196 related articles for article (PubMed ID: 30985223)
1. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
[No Abstract] [Full Text] [Related]
2. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
[TBL] [Abstract][Full Text] [Related]
4. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
5. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
Tarallo M; Onishchenko K; Alexopoulos ST
J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
[No Abstract] [Full Text] [Related]
8. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
[TBL] [Abstract][Full Text] [Related]
9. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
Scherlinger M; Langlois E; Germain V; Schaeverbeke T
Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar versus originator etanercept: a real-life clinical study.
Giordano D; Capalbo A; Gagliostro N; Fedele G; Balampanos CG; Persechino F; Bushati V; Ulisse S; Persechino S; Pellacani G
Ital J Dermatol Venerol; 2022 Aug; 157(4):318-324. PubMed ID: 35274881
[TBL] [Abstract][Full Text] [Related]
11. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.
Glintborg B; Ibsen R; Bilbo REQ; Lund Hetland M; Kjellberg J
RMD Open; 2019; 5(2):e001016. PubMed ID: 31452931
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
13. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.
Cantini F; Benucci M
Ann Rheum Dis; 2020 Feb; 79(2):e13. PubMed ID: 30487149
[No Abstract] [Full Text] [Related]
14. Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.
Burness CB; Duggan ST
BioDrugs; 2016 Aug; 30(4):371-8. PubMed ID: 27455991
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study.
Sakane H; Yonemoto Y; Okamura K; Suto T; Inoue M; Mitomi H; Tsuchida K; Kaneko T; Tamura Y; Chikuda H
J Orthop Surg (Hong Kong); 2024; 32(2):10225536241265818. PubMed ID: 38907590
[No Abstract] [Full Text] [Related]
16. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Haugeberg G; Bakland G; Rødevand E; Hansen IJW; Diamantopoulos A; Pripp AH
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1986-1995. PubMed ID: 36722450
[TBL] [Abstract][Full Text] [Related]
18. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study.
Giunta A; Manfreda V; Esposito M; Del Duca E; Bianchi L
Br J Dermatol; 2019 Nov; 181(5):1078-1079. PubMed ID: 31049938
[No Abstract] [Full Text] [Related]
19. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
20. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
